Literature DB >> 22086414

Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.

Graça M Dores1, Susan S Devesa, Rochelle E Curtis, Martha S Linet, Lindsay M Morton.   

Abstract

Since 2001, the World Health Organization classification for hematopoietic and lymphoid neoplasms has provided a framework for defining acute leukemia (AL) subtypes, although few population-based studies have assessed incidence patterns and patient survival accordingly. We assessed AL incidence rates (IRs), IR ratios (IRRs), and relative survival in the United States (2001-2007) in one of the first population-based, comprehensive assessments. Most subtypes of acute myeloid leukemia (AML) and acute lymphoblastic leukemia/lymphoma (ALL/L) predominated among males, from twice higher incidence of T-cell ALL/L among males than among females (IRR = 2.20) to nearly equal IRs of acute promyelocytic leukemia (APL; IRR = 1.08). Compared with non-Hispanic whites, Hispanics had significantly higher incidence of B-cell ALL/L (IRR = 1.64) and APL (IRR = 1.28); blacks had lower IRs of nearly all AL subtypes. All ALL/L but only some AML subtypes were associated with a bimodal age pattern. Among AML subtypes, survival was highest for APL and AML with inv(16). B-cell ALL/L had more favorable survival than T-cell ALL/L among the young; the converse occurred at older ages. Limitations of cancer registry data must be acknowledged, but the distinct AL incidence and survival patterns based on the World Health Organization classification support biologic diversity that should facilitate etiologic discovery, prognostication, and treatment advances.

Entities:  

Mesh:

Year:  2011        PMID: 22086414      PMCID: PMC3251235          DOI: 10.1182/blood-2011-04-347872

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  Clinical importance of cytogenetics in acute myeloid leukaemia.

Authors:  K Mrózek; K Heinonen; C D Bloomfield
Journal:  Best Pract Res Clin Haematol       Date:  2001-03       Impact factor: 3.020

2.  Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites.

Authors:  Matthew J Matasar; Ellen K Ritchie; Nathan Consedine; Carol Magai; Alfred I Neugut
Journal:  Leuk Lymphoma       Date:  2006-11

3.  Karyotype and age in acute myeloid leukemia. Are they linked?

Authors:  A V Moorman; E Roman; E V Willett; G J Dovey; R A Cartwright; G J Morgan
Journal:  Cancer Genet Cytogenet       Date:  2001-04-15

4.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

Authors:  D Grimwade; H Walker; G Harrison; F Oliver; S Chatters; C J Harrison; K Wheatley; A K Burnett; A H Goldstone
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

5.  Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience.

Authors:  U H Athale; B I Razzouk; S C Raimondi; X Tong; F G Behm; D R Head; D K Srivastava; J E Rubnitz; L Bowman; C H Pui; R C Ribeiro
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

6.  The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation.

Authors:  M Vickers; G Jackson; P Taylor
Journal:  Leukemia       Date:  2000-04       Impact factor: 11.528

7.  More on geographic hematology: the breakpoint cluster regions of the PML/RARalpha fusion gene in Mexican Mestizo patients with promyelocytic leukemia are different from those in Caucasians.

Authors:  Guillermo J Ruiz-Argüelles; Javier Garcés-Eisele; Virginia Reyes-Núñez; José David Gómez-Rangel; Guillermo J Ruiz-Delgado
Journal:  Leuk Lymphoma       Date:  2004-07

Review 8.  Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene.

Authors:  Dan Douer; Sergio Santillana; Laleh Ramezani; Cesar Samanez; Marilyn L Slovak; Ming S Lee; Kristy Watkins; Tony Williams; Carlos Vallejos
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

9.  Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up.

Authors:  J Thiele; H M Kvasnicka; G Zerhusen; J Vardiman; V Diehl; M Luebbert; A Schmitt-Graeff
Journal:  Ann Hematol       Date:  2004-06-02       Impact factor: 3.673

10.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Authors:  D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

View more
  188 in total

1.  Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy.

Authors:  Lori Muffly; Richard A Larson
Journal:  Transl Pediatr       Date:  2012-10

2.  Myeloid sarcoma causing airway obstruction.

Authors:  Aaron R Belknap; John R Krause
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

Review 3.  Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

Authors:  Joseph Wynne; David Wright; Wendy Stock
Journal:  Blood Adv       Date:  2019-01-08

4.  Childhood leukemia incidence in California: High and rising in the Hispanic population.

Authors:  Brenda M Giddings; Todd P Whitehead; Catherine Metayer; Mark D Miller
Journal:  Cancer       Date:  2016-06-28       Impact factor: 6.860

Review 5.  Blinatumomab for the treatment of acute lymphoblastic leukemia.

Authors:  Jason B Kaplan; Marina Grischenko; Francis J Giles
Journal:  Invest New Drugs       Date:  2015-09-17       Impact factor: 3.850

6.  Antiproliferative effect of upregulation of hsa-let-7c-5p in human acute erythroleukemia cells.

Authors:  Deniz Mortazavi; Mohammadreza Sharifi
Journal:  Cytotechnology       Date:  2018-08-02       Impact factor: 2.058

7.  Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.

Authors:  Andrea R Hagemann; Akiva P Novetsky; Israel Zighelboim; Feng Gao; L Stewart Massad; Premal H Thaker; Matthew A Powell; David G Mutch; Jason D Wright
Journal:  Gynecol Oncol       Date:  2013-10-04       Impact factor: 5.482

Review 8.  Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.

Authors:  Alan S Gamis; Todd A Alonzo; John P Perentesis; Soheil Meshinchi
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 9.  Recent Advances in the Management of Acute Lymphoblastic Leukaemia.

Authors:  Katharine A Hodby; David I Marks
Journal:  Curr Treat Options Oncol       Date:  2020-02-20

10.  Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival.

Authors:  A G Dinmohamed; A Szabó; M van der Mark; O Visser; P Sonneveld; J J Cornelissen; M Jongen-Lavrencic; A W Rijneveld
Journal:  Leukemia       Date:  2015-08-19       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.